D-0267-2019 Class II Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

FDA drug recall D-0267-2019 was initiated by Sciegen Pharmaceuticals Inc on Oct 29, 2018 and is designated Class II. Reason for recall: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product. The recall status is terminated (terminated Sep 25, 2023). Affected quantity: 2,977 HDPE bottles.

Recall details

Product Type
Drugs
Report Date
Nov 28, 2018
Initiation Date
Oct 29, 2018
Termination Date
Sep 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,977 HDPE bottles

Product description

Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-119-01), (b) 90-count bottle (NDC 69367-119-03), Rx Only, Manufactured by ScieGen Pharmaceuticals Inc Hauppauge, NY 11755 Manufactured for Westminister Pharmaceuticals LLC Olive Branch, MS 20854 Made in the USA

Reason for recall

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Distribution pattern

Nationwide

Code information

69367-119-01 Irbesartan 75mg Tablets, 30 count bottle B160002A Sep-19 69367-119-03 Irbesartan 75mg Tablets, 90 count bottle B160002B Sep-19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0267-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0267-2019. Report a data issue: hello@regdatalab.com.